Shanghai Fosun Pharmaceutical's 2024 ESG Report: Continuous innovation illuminating the sustainable development of inclusive healthcare.

On April 7, 2025, Shanghai Fosun Pharmaceutical (02196, 600196.SH) released the "2024 Environmental, Social, and Governance (ESG) and Sustainable Development Report" (hereinafter referred to as the "Report"), marking the 17th consecutive year that the company has comprehensively demonstrated its practices and achievements in environmental protection, social responsibility, and corporate governance to stakeholders. Currently, promoting high-quality development has become a consensus and conscious action throughout society, and the introduction and practice of ESG concepts provide a strong lever for sustainable and high-quality economic and social development. As an innovative, globally-oriented healthcare industry group, Shanghai Fosun Pharmaceutical has always adhered to the mission of "letting every family enjoy health" and actively practices ESG concepts, integrating ESG into its development strategy and operational activities to contribute to the high-quality development of the industry and society. In order to promote the high-quality development and investment value enhancement of listed companies, and regulate the disclosure of sustainable development-related information by listed companies, the Shanghai Stock Exchange issued the "Shanghai Stock Exchange Listed Company Self-Regulation Guidelines No. 14 - Sustainable Development Report (Trial)" in April 2024 (hereinafter referred to as the "Guidelines"). As a company listed on both the A+H stock markets, Shanghai Fosun Pharmaceutical has identified 14 sustainable development issues that are important to the Group for focused disclosure in accordance with the Guidelines, with four issues being of dual importance, including innovation drive, product and service safety and quality, environmental management, and climate change response. In addition to continuously improving ESG disclosure, the Report also follows the Hong Kong Stock Exchange Listing Rules Appendix C2 "Code on Environmental, Social and Governance Reporting" and complies with the Global Sustainability Standards Board (GSSB) "Sustainability Reporting Standards" (2021 edition, referred to as "GRI Standards"). In 2024, Shanghai Fosun Pharmaceutical excelled in the field of ESG, maintaining MSCI ESG Rating A and Hang Seng ESG Rating A-, and receiving numerous awards such as the 2024 China ESG 50 List (Forbes) and the China ESG Listed Companies Pioneer 100 (CCTV). Additionally, its rural doctor public welfare case was selected as an "Outstanding Practice Case of Rural Revitalization for Listed Companies in 2024" by the China Listed Companies Association in January 2025, demonstrating the social responsibility commitment of outstanding enterprises in the pharmaceutical industry. Shanghai Fosun Pharmaceutical has always considered innovation as its most important social responsibility, focusing on unmet clinical needs and continuously improving drug accessibility and affordability through diverse innovation models such as independent research and development and licensed introductions to promote global equitable access to health. Furthermore, Shanghai Fosun Pharmaceutical has been committed to enhancing the medical level in developing countries, particularly in Africa, by supporting medical construction in developing countries through measures such as drug supply, technical training, and localized production to strengthen public health capacity. In terms of social welfare, in response to the national rural revitalization strategy, Shanghai Fosun Pharmaceutical has actively participated in the "Rural Doctor Project" through the Xing Ai 121 Special Public Welfare Fund, protecting 25,000 village doctors and benefiting 3 million rural families. Moreover, the "Pink Blue Ribbon Public Welfare Tour" two-cancer screening project covers Yunnan, Sichuan, and other regions, benefiting over 16,000 people and effectively improving grassroots medical service capabilities. Over the past three years, Shanghai Fosun Pharmaceutical Group's total public welfare donations exceeded 300 million yuan. In environmental protection, Shanghai Fosun Pharmaceutical promotes green development and a dual-carbon strategy, actively addressing the challenges of climate change to promote harmonious development among enterprises, society, and the environment, and to build a green and beautiful homeland. In 2024, Shanghai Fosun Pharmaceutical invested nearly 110 million yuan in environmental protection. ESG has become an important consideration in capital market investments, and domestic regulatory agencies are increasingly emphasizing ESG. Shanghai Fosun Pharmaceutical attaches importance to the long-term governance capacity of ESG and has established an ESG governance structure consisting of a board of directors, ESG committees, ESG management committees, and ESG working groups to ensure effective supervision, scientific guidance, and full support from the board of directors and management for sustainable development. Chairman of Shanghai Fosun Pharmaceutical, Wu Yifang, stated: "2024 is an important year for Shanghai Fosun Pharmaceutical Group's progress in the field of ESG. In the future, we will continue to actively practice ESG concepts, adhere to innovation drive, develop safe and effective high-quality products, promote the development of global health business, and strive to 'let every family enjoy health'."